Aurinia Pharmaceuticals Inc.

AUPH Nasdaq SEC CIK 1600620
Follow Aurinia Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $83.7M +13.9% vs same quarter last year
Net income $31.7M +0.5% vs same quarter last year
EPS, diluted $0.23 +0% vs same quarter last year
Operating cash flow $46.4M +4.3% vs same quarter last year
Revenue by quarter
$59.9M
$62.5M
$70M
$73.5M
$77.1M
$77.7M
$83.2M
$83.7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$200M$0$200M$400MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$283.1M$287.2M
FY24$235.1M$5.8M
FY23$175.5M−$78M
FY22$134M−$108.2M
FY21$45.6M−$181M
FY20$50.1M−$102.7M
FY19$318K−$88.4M
FY18$463K−$53.1M
FY17--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−30000%−20000%−10000%0%10000%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2588.5%37.1%101.5%
FY2488%−2%2.5%
FY2391.9%−52.2%−44.4%
FY2295.8%−83.2%−80.7%
FY2197.6%−396.3%−396.9%
FY20100%−208.1%−204.9%
FY19100%−28598.4%−27794%
FY18-−11930.9%−11464.1%
FY17---
Returned to shareholdersDividends paid and shares bought back
$0$25M$50M$75M$100MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBuybacks
FY25$98.2M
FY24$40.2M
FY23$0
FY22$0
FY21-
FY20-
FY19-
FY18-
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Aurinia Pharmaceuticals
  • Healthcare median
−30000%−20000%−10000%0%10000%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearAurinia PharmaceuticalsHealthcare median
FY25101.5%−30.6%
FY242.5%−47%
FY23−44.4%−58%
FY22−80.7%−80.4%
FY21−396.9%−71.9%
FY20−204.9%−62.2%
FY19−27794%−46.3%
FY18−11464.1%−49.6%
FY17-−45.9%